Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell Lines in vitro

• Published in: European journal of cancer (1990) Vol. 31; no. 1; pp. 92 - 97
• Main Authors: Vanhoefer, U., Harstrick, A., Wilke, H., Schleucher, N., Walles, H., Schröder, J., Seeber, S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 1995
• Subjects: Cell Cycle - drug effects; Cell Survival - drug effects; cisplatin; Cisplatin - administration & dosage; Cisplatin - metabolism; Cisplatin - pharmacology; Drug Administration Schedule; drug interaction; Drug Screening Assays, Antitumor; Female; gastric cancer; Glutathione - metabolism; glutathione pathway; Humans; ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - metabolism; paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - antagonists & inhibitors; Paclitaxel - metabolism; pharmacokinetics; Stomach Neoplasms - drug therapy; Stomach Neoplasms - metabolism; Tumor Cells, Cultured - drug effects; paclitaxel; gastric cancer; ovarian cancer; drug interaction; glutathione pathway; pharmacokinetics; cisplatin
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(94)00440-G

Paclitaxel has demonstrated broad clinical activity in a variety of malignancies both alone and in combination with other chemotherapeutic agents. The in vitro cytotoxicity of paclitaxel and cisplatin alone, in combination and in sequence, were evaluated against established human gastric and ovarian carcinoma cell lines using 2-h drug exposure. The combination of cisplatin and paclitaxel was found to be additive or even synergistic when paclitaxel was given 24 h prior to cisplatin as demonstrated by isobologram analysis. However, when both drugs were given simultaneously or when cisplatin was given prior to paclitaxel, a strong antagonistic interaction was observed. This antagonism was evident for up to 72 h after a 2-h exposure to cisplatin. Pretreatment with cisplatin caused no alteration in [ 3H]paclitaxel uptake in HM2 gastric carcinoma cells, but resulted in decreased intracellular retention of paclitaxel. Since cisplatin treatment led to a reduction in cellular glutathione content in these cells and reduced levels of glutathione have been associated with protection against cytotoxicity of paclitaxel, cells were pretreated with L-buthionine sulfoximine (L-BSO). However, depletion of glutathione had no influence on the activity of paclitaxel. A significant accumulation of cells in S-phase was observed 24 h after cisplatin, which resolved after 48 h and resulted in a pronounced increase of G 2M phase. These data demonstrate that the interactions of paclitaxel and cisplatin are highly schedule-dependent and applications of cisplatin simultaneously with or prior to paclitaxel may result in pronounced antagonism. These findings could have implications for the design of further clinical protocols.